Abstract

BackgroundSuccessful gene therapy will require targeted delivery vectors capable of self-directed localization. In this regard, the use of antibodies or single chain antibody fragments (scFv) in conjunction with adenovirus (Ad) vectors remains an attractive means to achieve cell-specific targeting. However, a longstanding barrier to the development of Ad vectors with genetically incorporated scFvs has been the biosynthetic incompatibility between Ad capsid proteins and antibody-derived species. Specifically, scFv require posttranslational modifications not available to Ad capsid proteins due to their cytoplasmic routing during protein synthesis and virion assembly.Methodology/Principal FindingsWe have therefore sought to develop scFv-targeted Ad vectors using a secreted scFv that undergoes the requisite posttranslational modifications and is trafficked for secretion. Formation of the scFv-targeted Ad vector is achieved via highly specific association of the Ad virion and a targeting scFv employing synthetic leucine zipper-like dimerization domains (zippers) that have been optimized for structural compatibility with the Ad capsid and for association with the secreted scFv. Our results show that zipper-containing Ad fiber molecules trimerize and incorporate into mature virions and that zippers can be genetically fused to scFv without ablating target recognition. Most importantly, we show that zipper-tagged virions and scFv provide target-specific gene transfer.Conclusions/SignificanceThis work describes a new approach to produce targeted Ad vectors using a secreted scFv molecule, thereby avoiding the problem of structural and biosynthetic incompatibility between Ad and a complex targeting ligand. This approach may facilitate Ad targeting using a wide variety of targeting ligands directed towards a variety of cellular receptors.

Highlights

  • Successful gene therapy will require both rational vector development and exploitation of disease-specific cellular physiology to design targeted gene delivery vectors

  • Vectors based on human adenovirus (Ad) serotypes 2 and 5 of species C continue to show increasing promise as gene delivery vehicles due to several key attributes: Ad vectors display in vivo stability and excellent gene transfer efficiency to numerous dividing and non-dividing cell targets, do not integrate into the host genome, and are rarely linked to any severe disease in immunocompetent humans

  • We have developed a system that maintains the divergent biosynthetic pathways of the antibody and adenovirus components via use of a secreted scFv molecule encoded by the vector

Read more

Summary

Introduction

Successful gene therapy will require both rational vector development and exploitation of disease-specific cellular physiology to design targeted gene delivery vectors. Antibodies and recombinant antibody binding domains are potentially useful agents to achieve cell-specific targeting, due to their unparalleled affinity and specificity of binding to a wide range of target cell surface markers. On this basis, the development of Ad vectors with genetically incorporated antibody-derived moieties has been a long-standing goal. Successful gene therapy will require targeted delivery vectors capable of self-directed localization In this regard, the use of antibodies or single chain antibody fragments (scFv) in conjunction with adenovirus (Ad) vectors remains an attractive means to achieve cell-specific targeting. ScFv require posttranslational modifications not available to Ad capsid proteins due to their cytoplasmic routing during protein synthesis and virion assembly

Objectives
Methods
Results
Conclusion

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.